The State Commission for the Protection of Economic Competition of the Republic of Armenia General competition issues in parallel import of drugs Manuk Mikayelyan, Head of Department Velikiy Novgorod, September 2017
In 2017 The Commission received a statement from economic entities involved in the import and distribution of medicinal products on the territory of the Republic of Armenia. According to the position of economic entities - the Ministry of Health (Ministry) refused to allow certain medicines to be imported into the Republic of Armenia, which helped to restrict competition in the pharmaceutical market. 2 According to the position of the Ministry - the aforementioned refusals are due to the fact that some differences were detected between registered and imported medicines, so they were considered unregistered. As a result of the Commission's studies conducted in 2013-2015, a number of provisions restricting competition have been identified in legal acts regulating the import and registration of medicines. To solve the identified problems, the Commission provided relevant information to the Government of Armenia, proposing amendments to these acts, finalizing and introducing a full-fledged procedure for parallel importation of medicines. As a result, the new drug law, adopted in 2016, finalized and introduced the parallel import procedure. Currently, there are problems with the full operation of the parallel import system, as existing legal regulations require that imported and registered drugs are identical, while pharmaceutical companies provide the same drug to different countries with some differences.
Producer of the drug Merck KGaA (Germany). Form issued in the Republic of Armenia (2 × 25, 2 blisters with 25 tablets each). The form of release of the imported preparation (5 × 10, 5 blisters with 10 tablets each). As a result of the study, it was found out before March 27, 2017 that the drug was registered in the Republic of Armenia with a package of 5 × 10, and then the above change was made 3 Registered drug Imported drug Price difference – 30%
Производитель лекарства Medana Pharma (Польша). В Армении препарат был зарегистрирован под торговым наименованием Аквадетрим витамин Медана. 4 Registered drug Imported drug Price difference – 71%
Manufacturer; Polpharma (Poland). 5 Registered drug Imported drug Price difference – 206%
Manufacturer: Berlin-Chemie AG (Germany). 6 Registered drug Imported drug Price difference – 88%